Kernicterus Treatment Market Report 2026

Kernicterus Treatment Market Overview

• Kernicterus Treatment market size has reached to $3.03 billion in 2025 • Expected to grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 2.2% • Growth Driver: The Prevalence Of Neonatal Jaundice Is Fueling The Market Growth Due To Increasing Demand For Advanced Bilirubin Management Therapies • Market Trend: Innovative Solutions For Early Detection And Treatment Of Neonatal Jaundice • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Kernicterus Treatment Market?

Kernicterus treatment refers to the medical interventions used to prevent or manage kernicterus, a severe and permanent form of brain damage that occurs in newborns due to excessively high levels of unconjugated bilirubin (severe neonatal hyperbilirubinemia). The primary goal of treatment is to rapidly reduce bilirubin levels and prevent bilirubin from crossing the blood–brain barrier, thereby minimizing neurological damage. The main types of kernicterus treatment are phototherapy, exchange transfusion, pharmacological supportive therapy, and supportive neurological care. Phototherapy is a medical treatment that uses specific wavelengths of light to treat certain conditions by triggering beneficial biological effects in the body. In neonatal care, phototherapy is most commonly used to treat hyperbilirubinemia (jaundice) in newborns. Treatment is administered via non-invasive phototherapy (light-based), injectable blood products, IVIG, and albumin, and is used by end users such as hospitals, neonatal intensive care units (NICUs), specialty neonatal centers, and academic and research institutes.

What Is The Kernicterus Treatment Market Growth Forecast?

The kernicterus treatment market size is expected to see steady growth in the next few years. It will grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 2.2%. The growth in the forecast period can be attributed to advancements in laser and phototherapy technologies, rising awareness of scar management solutions, increasing preference for non-surgical treatments, expansion of dermatology clinics in emerging economies, growing adoption of at-home scar treatment products. Major trends in the forecast period include rising demand for minimally invasive keloid treatments, growing use of combination therapy approaches, increasing adoption of laser and phototherapy solutions, expansion of homecare and topical scar management products, focus on reducing keloid recurrence rates.

Global Kernicterus Treatment Market Segmentation

1) By Treatment Type: Phototherapy, Exchange Transfusion, Pharmacological Supportive Therapy, Supportive Neurological Care 2) By Route of Administration: Non-Invasive, Phototherapy (light-based), Injectable, Blood Products, IVIG, Albumin 3) By End User: Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Neonatal Centers, Academic And Research Institutes Subsegments: 1) By Phototherapy: Conventional Phototherapy, Intensive Phototherapy, LED-Based Phototherapy, Fiberoptic Phototherapy 2) By Exchange Transfusion: Partial Exchange Transfusion, Double Volume Exchange Transfusion 3) By Pharmacological Supportive Therapy: Intravenous Immunoglobulin (IVIG), Albumin Therapy 4) By Supportive Neurological Care: Seizure Management, Respiratory Support, Nutritional and Fluid Management

What Are The Drivers Of The Kernicterus Treatment Market?

The prevalence of neonatal jaundice is driving the growth of the kernicterus treatment market going forward. Neonatal jaundice, also known simply as jaundice in newborns, is a common and typically harmless condition characterized by the yellowing of a baby's skin and the whites of their eyes. Neonatal jaundice is rising due to increased rates of preterm births, as premature infants have underdeveloped liver function, making it harder for them to process and eliminate bilirubin effectively. Kernicterus treatment is commonly used for neonatal jaundice; IT manages the symptoms and provides supportive care. This procedure removes blood from the baby and replaces IT with blood with a lower bilirubin level, improving the affected child's quality of life. For instance, in October 2023, according to reports published by the National Library of Medicine, a US-based biomedical library, about 60% of term infants and 80% of preterm infants experience jaundice within their first week of life, and around 10% of breastfed infants remain jaundiced at one month of age. Therefore, the prevalence of neonatal jaundice is expected to propel the growth of the kernicterus treatment industry. Increasing healthcare spending is driving the growth of the kernicterus treatment market. Healthcare expenditure refers to the total spending on medical services, equipment, and technologies aimed at improving health outcomes. Healthcare expenditure is growing due to the increasing demand for advanced medical technologies, as hospitals and clinics invest more in innovative equipment and digital solutions to improve patient care and outcomes. Increasing healthcare spending supports kernicterus treatment by improving early detection of neonatal jaundice and ensuring timely, effective medical care that prevents severe brain damage. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based government agency, in 2023, national health expenditures (NHE) grew by 7.5%, reaching $4.9 trillion, which averages $14,570 per person and represents 17.6% of the Gross Domestic Product (GDP). Spending on Medicare increased by 8.1% to $1,029.8 billion, making up 21% of total NHE. Therefore, the rising healthcare expenditure is driving the growth of the kernicterus treatment industry.

Key Players In The Global Kernicterus Treatment Market

Major companies operating in the kernicterus treatment market are GE HealthCare, Philips Healthcare, Drägerwerk AG, Natus Medical Incorporated, Atom Medical Corporation, Phoenix Medical Systems, Fanem Ltda, Medela AG, Olympic Medical, Nice Neotech Medical Systems, Baxter International Inc., Fresenius Kabi, Grifols S.A, CSL Limited, Octapharma AG, Kedrion S.p.A, Biotest AG, Terumo Corporation, Haemonetics Corporation, Macopharma

Global Kernicterus Treatment Market Trends and Insights

Major companies and organizations operating in the kernicterus treatment market are increasingly focusing on developing innovative solutions such as integrated neonatal jaundice screening and advanced phototherapy systems to enable early diagnosis, ensure timely treatment, and prevent kernicterus-related neurological damage in newborns. Integrated neonatal jaundice screening and advanced phototherapy systems are combined diagnostic and treatment technologies that accurately measure bilirubin levels and deliver effective light therapy, helping by detecting jaundice early and safely reducing bilirubin levels to prevent kernicterus and long-term brain damage in newborns. For instance, in December 2024, the Wellbeing Foundation Africa (WBFA), a Nigeria-based non-governmental health organization, in collaboration with Reckitt, a UK-based consumer health company, launched Project Oscar – Light For Life, a nationwide neonatal jaundice screening, treatment, and kernicterus prevention initiative. The program provides healthcare facilities with modern phototherapy equipment and bilirubinometers, enabling accurate, early detection and effective treatment of neonatal jaundice, while also training healthcare professionals and educating mothers to dispel harmful myths. Unlike conventional fragmented care models, Project Oscar adopts a holistic prevention-focused approach, integrating technology, capacity building, and community awareness to reduce neonatal mortality and lifelong disabilities associated with kernicterus.

Regional Outlook

North America was the largest region in the kernicterus treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Kernicterus Treatment Market?

The kernicterus treatment market consists of revenues earned by entities by providing services such as diagnosis and monitoring of neonatal hyperbilirubinemia, administration of phototherapy, exchange transfusion procedures, pharmacological supportive care, and neurological follow-up and management. The market value includes the value of related goods sold by the service provider or included within the service offering. The kernicterus treatment market also includes sales of phototherapy devices, blood and blood products for exchange transfusion, intravenous immunoglobulin (IVIG), albumin, and other supportive therapeutic products used in kernicterus management. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Kernicterus Treatment Market Report 2026?

The kernicterus treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the kernicterus treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.